DnB Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $47.9M | Sell |
107,311
-12,374
| -10% | -$5.77M | 0.17% | 96 |
|
|
2025
Q4 | $54.3M | Buy |
119,685
+24,271
| +25% | +$10.5M | 0.19% | 79 |
|
|
2025
Q3 | $37.4M | Buy |
95,414
+8,483
| +10% | +$3.55M | 0.14% | 107 |
|
|
2025
Q2 | $38.7M | Sell |
86,931
-89,600
| -51% | -$41.3M | 0.16% | 100 |
|
|
2025
Q1 | $85.6M | Sell |
176,531
-24,411
| -12% | -$11.4M | 0.39% | 52 |
|
|
2024
Q4 | $80.9M | Buy |
200,942
+19,289
| +11% | +$8.94M | 0.35% | 45 |
|
|
2024
Q3 | $84.5M | Buy |
181,653
+14,931
| +9% | +$7.17M | 0.38% | 47 |
|
|
2024
Q2 | $78.1M | Sell |
166,722
-24,528
| -13% | -$10.6M | 0.37% | 48 |
|
|
2024
Q1 | $79.9M | Sell |
191,250
-7,168
| -4% | -$3.03M | 0.42% | 41 |
|
|
2023
Q4 | $80.7M | Buy |
198,418
+6,211
| +3% | +$2.29M | 0.42% | 44 |
|
|
2023
Q3 | $66.8M | Sell |
192,207
-16,398
| -8% | -$5.73M | 0.4% | 50 |
|
|
2023
Q2 | $73.4M | Sell |
208,605
-75,042
| -26% | -$25.3M | 0.42% | 51 |
|
|
2023
Q1 | $89.4M | Sell |
283,647
-16,116
| -5% | -$4.83M | 0.57% | 38 |
|
|
2022
Q4 | $86.6M | Sell |
299,763
-16,219
| -5% | -$4.94M | 0.61% | 32 |
|
|
2022
Q3 | $91.5M | Sell |
315,982
-29,221
| -8% | -$8.41M | 0.71% | 25 |
|
|
2022
Q2 | $97.3M | Sell |
345,203
-6,275
| -2% | -$1.68M | 0.68% | 30 |
|
|
2022
Q1 | $91.7M | Sell |
351,478
-136,417
| -28% | -$32.4M | 0.55% | 37 |
|
|
2021
Q4 | $107M | Sell |
487,895
-22,007
| -4% | -$4.28M | 0.63% | 29 |
|
|
2021
Q3 | $92.5M | Buy |
509,902
+86,593
| +20% | +$16.9M | 0.6% | 29 |
|
|
2021
Q2 | $85.4M | Buy |
423,309
+349,530
| +474% | +$73.1M | 0.57% | 28 |
|
|
2021
Q1 | $15.9M | Buy |
73,779
+35,326
| +92% | +$7.76M | 0.12% | 140 |
|
|
2020
Q4 | $9.09M | Buy |
38,453
+3,718
| +11% | +$853K | 0.08% | 186 |
|
|
2020
Q3 | $9.45M | Buy |
34,735
+2,575
| +8% | +$710K | 0.1% | 151 |
|
|
2020
Q2 | $9.34M | Buy |
32,160
+5,256
| +20% | +$1.42M | 0.11% | 144 |
|
|
2020
Q1 | $6.4M | Sell |
26,904
-5,238
| -16% | -$1.2M | 0.09% | 159 |
|
|
2019
Q4 | $7.04M | Buy |
32,142
+4,397
| +16% | +$890K | 0.07% | 196 |
|
|
2019
Q3 | $4.7M | Buy |
27,745
+1,944
| +8% | +$344K | 0.05% | 250 |
|
|
2019
Q2 | $4.73M | Sell |
25,801
-1,635
| -6% | -$286K | 0.05% | 242 |
|
|
2019
Q1 | $5.05M | Sell |
27,436
-3,084
| -10% | -$570K | 0.06% | 215 |
|
|
2018
Q4 | $5.06M | Sell |
30,520
-2,104
| -6% | -$365K | 0.07% | 202 |
|
|
2018
Q3 | $6.29M | Buy |
32,624
+1,044
| +3% | +$186K | 0.07% | 192 |
|
|
2018
Q2 | $5.37M | Buy |
31,580
+2,400
| +8% | +$372K | 0.06% | 208 |
|
|
2018
Q1 | $4.76M | Buy |
29,180
+2,900
| +11% | +$474K | 0.06% | 218 |
|
|
2017
Q4 | $3.94M | Buy |
26,280
+600
| +2% | +$88.8K | 0.05% | 246 |
|
|
2017
Q3 | $3.9M | Sell |
25,680
-100
| -0.4% | -$15.1K | 0.05% | 226 |
|
|
2017
Q2 | $3.32M | Sell |
25,780
-700
| -3% | -$84.3K | 0.05% | 245 |
|
|
2017
Q1 | $2.9M | Buy |
26,480
+4,100
| +18% | +$361K | 0.05% | 266 |
|
|
2016
Q4 | $1.65M | Buy |
22,380
+1,200
| +6% | +$97.6K | 0.03% | 322 |
|
|
2016
Q3 | $1.85M | Buy |
21,180
+1,400
| +7% | +$132K | 0.04% | 298 |
|
|
2016
Q2 | $1.7M | Buy |
19,780
+1,500
| +8% | +$130K | 0.04% | 294 |
|
|
2016
Q1 | $1.45M | Buy |
18,280
+4,700
| +35% | +$425K | 0.03% | 318 |
|
|
2015
Q4 | $1.71M | Sell |
13,580
-18,385
| -58% | -$2.22M | 0.04% | 248 |
|
|
2015
Q3 | $3.33M | Sell |
31,965
-20,125
| -39% | -$2.59M | 0.08% | 166 |
|
|
2015
Q2 | $6.43M | Buy |
52,090
+9,500
| +22% | +$1.2M | 0.14% | 126 |
|
|
2015
Q1 | $5.02M | Sell |
42,590
-13,700
| -24% | -$1.64M | 0.11% | 143 |
|
|
2014
Q4 | $6.69M | Buy |
56,290
+1,100
| +2% | +$124K | 0.15% | 124 |
|
|
2014
Q3 | $6.2M | Buy |
55,190
+20,110
| +57% | +$1.91M | 0.14% | 121 |
|
|
2014
Q2 | $3.32M | Buy |
+35,080
| New | +$2.46M | 0.07% | 176 |
|
|
2013
Q4 | $4.69M | Buy |
+63,080
| New | +$4.39M | 0.11% | 126 |
|
Other funds holding VRTX
VCM
VPM
DnB Asset Management's VRTX Position: Q1 2026 in Review
DnB Asset Management reduced its Vertex Pharmaceuticals (VRTX) stake by 10% in Q1 2026, selling an estimated $5.77M and leaving 107,311 shares worth $47.9M. The position accounts for 0.17% of the portfolio, ranked #96.
DnB Asset Management first reported a position in VRTX in Q4 2013 and has held it in 49 quarters since. The position peaked at $107M in Q4 2021. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- DnB Asset Management held 107,311 shares of Vertex Pharmaceuticals worth $47.9M as of Q1 2026.
- DnB Asset Management sold 12,374 Vertex Pharmaceuticals shares in Q1 2026, an estimated $5.77M.
- Vertex Pharmaceuticals made up 0.17% of DnB Asset Management's portfolio in Q1 2026, its #96 holding.
- DnB Asset Management first reported a position in Vertex Pharmaceuticals in Q4 2013 and has held it in 49 quarters since.
- DnB Asset Management's Vertex Pharmaceuticals position peaked at $107M in Q4 2021.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on DnB Asset Management's 13F filing for Q1 2026, filed 14 May 2026.